Non-Pulmonary Tuberculosis Disease Management

Standard Treatment Regimen for Most Non-Pulmonary TB Sites

The American Thoracic Society recommends a 6-month short-course regimen for most forms of non-pulmonary tuberculosis, consisting of 2 months of isoniazid, rifampin, pyrazinamide, and ethambutol (HRZE) followed by 4 months of isoniazid and rifampin (HR) 1, 2
The initial phase of treatment can be administered daily or three times weekly under directly observed therapy, with isoniazid (5 mg/kg up to 300 mg daily), rifampin (10 mg/kg up to 600 mg daily), pyrazinamide (35 mg/kg daily for patients <50 kg; 2.0 g daily for patients >50 kg), and ethambutol (15 mg/kg daily) 1, 2

The standard 6-month regimen (2HRZE/4HR) is recommended for peripheral lymph node TB, with nodes that may enlarge, new nodes that may develop, or abscesses that may form during or after treatment without indicating treatment failure or relapse 1, 2
For bone and joint TB, including spinal TB, the standard 6-month regimen is effective, with ambulatory chemotherapy being highly effective for thoracic and lumbar spine disease, and surgery plus chemotherapy required only for patients with spinal cord compression or spinal instability 1, 2
For tuberculous pericarditis, the standard 6-month regimen is used, with corticosteroids (prednisolone 60 mg/day initially, tapering over several weeks) added for acute constrictive pericarditis or pericardial effusion, which has demonstrated clear benefit in preventing cardiac constriction 1, 2
For TB meningitis and CNS tuberculosis, treatment duration is extended to 12 months total, with 2 months of HRZE followed by 10 months of HR, and corticosteroids administered for more severe disease (stages II and III) to prevent neurologic sequelae 1, 2

Drug susceptibility testing should be performed on all initial isolates from patients with TB, with the regimen altered appropriately once susceptibility results are available 3
Directly observed therapy is strongly recommended for all TB patients to ensure treatment completion and prevent drug resistance 3